Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

Background and objectives The 52‐week, randomized, double‐blind, noninferiority, government‐funded NOR ‐ SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT ‐P13 was not inferior to continued treatment with infliximab originator. The NOR ‐ SWITCH extension trial aimed to assess efficacy, safety and immunogenicity in patients on CT ‐P13 throughout the 78‐week study period (maintenance group) versus...